At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 499 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Randomized, Open-Label, Parallel-Group Comparative Study: Atorvastatin Pre-Treatment Versus Usual Care In Asian Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Aug 6, 2008·Updated Feb 21, 2021
In Brief
A Phase 4 clinical trial evaluating Atorvastatin for Acute Coronary Syndrome. Completed, enrolled 499 participants across 26 sites in 2 countries.
Detailed Summary
This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesChina, South Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2008
Enrollment StartSep 2008
Primary CompletionApr 2010
TodayJul 2026
First PostedAug 6, 2008
Enrollment StartSep 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.9 years ago
Interventions
Atorvastatindrug
80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
Atorvastatindrug
40mg daily after PCI for 30 days.